Cargando…

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations

INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin...

Descripción completa

Detalles Bibliográficos
Autores principales: Margetić, Sandra, Ćelap, Ivana, Delić Brkljačić, Diana, Pavlović, Nikola, Šupraha Goreta, Sandra, Kobasić, Ivana, Lovrenčić-Huzjan, Arijana, Bašić Kes, Vanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Society of Medical Biochemistry and Laboratory Medicine 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904970/
https://www.ncbi.nlm.nih.gov/pubmed/31839722
http://dx.doi.org/10.11613/BM.2020.010702
_version_ 1783478084235689984
author Margetić, Sandra
Ćelap, Ivana
Delić Brkljačić, Diana
Pavlović, Nikola
Šupraha Goreta, Sandra
Kobasić, Ivana
Lovrenčić-Huzjan, Arijana
Bašić Kes, Vanja
author_facet Margetić, Sandra
Ćelap, Ivana
Delić Brkljačić, Diana
Pavlović, Nikola
Šupraha Goreta, Sandra
Kobasić, Ivana
Lovrenčić-Huzjan, Arijana
Bašić Kes, Vanja
author_sort Margetić, Sandra
collection PubMed
description INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. We aimed to evaluate relationship between anti-FXa methods calibrated with low molecular weight heparin (LMWH) and with drug specific calibrators, and to determine whether commercial LMWH anti-FXa assay can be used to exclude the presence of clinically relevant concentrations of rivaroxaban and apixaban. MATERIALS AND METHODS: Low molecular weight heparin calibrated reagent (Siemens Healthineers, Marburg, Germany) was used for anti-FXa activity measurement. Innovance heparin (Siemens Healthineers, Marburg, Germany) calibrated with rivaroxaban and apixaban calibrators (Hyphen BioMed, Neuville-sur-Oise, France) was used for quantitative determination of FXa inhibitors. RESULTS: Analysis showed good agreement between LMWH calibrated and rivaroxaban calibrated activity (κ = 0.76) and very good agreement with apixaban calibrated anti-Xa activity (κ = 0.82), respectively. Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/mL are suitable for excluding the presence of clinically relevant concentrations (< 30 ng/mL) of rivaroxaban and apixaban, respectively. Concentrations above 300 ng/mL exceeded upper measurement range for LMWH anti-FXa assay and cannot be determined by this method. CONCLUSION: Low molecular weight heparin anti-FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban. However, use of LMWH anti-FXa assay is not appropriate for their quantitative determination as an interchangeable method.
format Online
Article
Text
id pubmed-6904970
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Croatian Society of Medical Biochemistry and Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-69049702019-12-15 Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations Margetić, Sandra Ćelap, Ivana Delić Brkljačić, Diana Pavlović, Nikola Šupraha Goreta, Sandra Kobasić, Ivana Lovrenčić-Huzjan, Arijana Bašić Kes, Vanja Biochem Med (Zagreb) Original Articles INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. We aimed to evaluate relationship between anti-FXa methods calibrated with low molecular weight heparin (LMWH) and with drug specific calibrators, and to determine whether commercial LMWH anti-FXa assay can be used to exclude the presence of clinically relevant concentrations of rivaroxaban and apixaban. MATERIALS AND METHODS: Low molecular weight heparin calibrated reagent (Siemens Healthineers, Marburg, Germany) was used for anti-FXa activity measurement. Innovance heparin (Siemens Healthineers, Marburg, Germany) calibrated with rivaroxaban and apixaban calibrators (Hyphen BioMed, Neuville-sur-Oise, France) was used for quantitative determination of FXa inhibitors. RESULTS: Analysis showed good agreement between LMWH calibrated and rivaroxaban calibrated activity (κ = 0.76) and very good agreement with apixaban calibrated anti-Xa activity (κ = 0.82), respectively. Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/mL are suitable for excluding the presence of clinically relevant concentrations (< 30 ng/mL) of rivaroxaban and apixaban, respectively. Concentrations above 300 ng/mL exceeded upper measurement range for LMWH anti-FXa assay and cannot be determined by this method. CONCLUSION: Low molecular weight heparin anti-FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban. However, use of LMWH anti-FXa assay is not appropriate for their quantitative determination as an interchangeable method. Croatian Society of Medical Biochemistry and Laboratory Medicine 2019-12-15 2020-02-15 /pmc/articles/PMC6904970/ /pubmed/31839722 http://dx.doi.org/10.11613/BM.2020.010702 Text en Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Margetić, Sandra
Ćelap, Ivana
Delić Brkljačić, Diana
Pavlović, Nikola
Šupraha Goreta, Sandra
Kobasić, Ivana
Lovrenčić-Huzjan, Arijana
Bašić Kes, Vanja
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
title Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
title_full Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
title_fullStr Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
title_full_unstemmed Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
title_short Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
title_sort chromogenic anti-fxa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904970/
https://www.ncbi.nlm.nih.gov/pubmed/31839722
http://dx.doi.org/10.11613/BM.2020.010702
work_keys_str_mv AT margeticsandra chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations
AT celapivana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations
AT delicbrkljacicdiana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations
AT pavlovicnikola chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations
AT suprahagoretasandra chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations
AT kobasicivana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations
AT lovrencichuzjanarijana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations
AT basickesvanja chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations